Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study

International Journal of Impotence Research volume 18, pages 550–558 (2006)Cite this article

Abstract

To evaluate the safety and efficacy of cabergoline in men with erectile dysfunction (ED) who did not respond to sildenafil. Four hundred two sildenafil nonresponders aged from 21 to 59 years were included in the study. Patients were randomly divided into group 1, those who received 0.5–1 mg cabergoline weekly for 6 months and group 2, who received placebo for the same period. They underwent preliminary assessment, including medical and sexual history, self-administered International Index of Erectile Function (IIEF) and intravaginal ejaculatory latency time (IVELT) evaluation. Standard biochemistry and hematological laboratory tests, and measurement of serum testosterone and prolactin levels were also carried out. When indicated, other tests were used to establish the diagnosis of vasculogenic and neurogenic ED, including penile color duplex Doppler ultrasonography, pudendal nerve conduction test and impaired sensory-evoked potentials studies. The efficacy of two treatments was assessed every 2 weeks during treatment, at the end of the study, using responses to IIEF, IVELT evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects. The trial was completed by 370 (92%) men. Positive clinical results were seen in 31.2% of patients in the cabergoline group compared with 7.1% of patients in the placebo group (P=0.04). The mean weekly intercourse episodes increased from pretreatment values of 1.4 and 1.2 to 2.2 and 1.4, for cabergoline and placebo, respectively (P=0.04). Baseline mean intercourse satisfaction domain values of IIEF 10 and 11 reached to 15 and 10 at 6-month treatment in groups 1 and 2, respectively (P=0.04). The IVELT after cabergoline and placebo gradually increased from 98 and 101 s to approximately 242 and 116 s, respectively (P=0.001). More drug-related adverse effects occurred in cabergoline group and 12 (5.9%) had to discontinue treatment (P=0.001). Cabergoline is moderately effective salvage therapy for sildenafil nonresponse. Further studies with different dosages and treatment regimens are necessary to draw final conclusions on the efficacy of this drug in ED.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397–1404.

    Article  CAS  Google Scholar 

  2. Padma-Nathan H, Shabsigh R . Sildenafil citrate (Viagra): a review. AUA Update Series, vol. XVIII, lesson 35, 1999.

  3. McCullough AR, Barada JH, Fawzy A, Guay AT, Hatzichristou D . Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology 2002; 60 (2 Suppl 2): 28–38.

    Article  Google Scholar 

  4. Souverein PC, Egberts AC, Meuleman EJ, Urquhart J, Leufkens HG . Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. Int J Impot Res 2002; 14: 259–265.

    Article  CAS  Google Scholar 

  5. Salonia A, Rigatti P, Montorsi F . Sildenafil in erectile dysfunction: a critical review. Curr Med Res Opin 2003; 19: 241–262.

    Article  CAS  Google Scholar 

  6. Althof SE . When an erection alone is not enough: biopsychosocial obstacles to lovemaking. Int J Impot Res 2002; 14 (Suppl 1): S99–S104.

    Article  Google Scholar 

  7. Pallas J, Levine SB, Althof SE, Risen CB . A study using Viagra in a mental health practice. J Sex Marital Ther 2000; 26: 41–50.

    Article  CAS  Google Scholar 

  8. Christiansen E, Guirguis WR, Cox D, Osterloh IH, Sildenafil Multicentre Study Group. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000; 12: 177–182.

    Article  CAS  Google Scholar 

  9. Jardin A, Wagner G, Khoury S, Giuliano F, Padma Nathan H, Rosen R . Presented at First International Consultation on Erectile Dysfunction: Sponsored by World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societé Internationale d'Urologie (SIU), Paris, France, July 1–3 1999.

  10. Giuliano F, Rampin O . Central neural regulation of penile erection. Neurosci Biobehav Rev 2000; 24: 517–533.

    Article  CAS  Google Scholar 

  11. Civelli O, Bunzow JR, Grandy DK . Molecular diversity of the dopamine receptors. Annu Rev Pharmacol Toxicol 1993; 33: 281–307.

    Article  CAS  Google Scholar 

  12. O'Dowd BF . Structures of dopamine receptors. J Neurochem 1993; 60: 804–816.

    Article  CAS  Google Scholar 

  13. Jenkins RB, Groh RH . Mental symptoms in Parkinsonian patients treated with L-dopa. Lancet 1970 25; 2: 177–179.

    Article  CAS  Google Scholar 

  14. Bowers Jr MB, Van Woert M, Davis L . Sexual behavior during L-dopa treatment for Parkinsonism. Am J Psychiatr 1971; 127: 1691–1693.

    Article  Google Scholar 

  15. Shapiro SK . Hypersexual behavior complicating levodopa (I-dopa) therapy. Minn Med 1973; 56: 58–59.

    CAS  PubMed  Google Scholar 

  16. Ferrari F, Ottani A, Giuliani D . Influence of sildenafil on copulatory behaviour in sluggish or normal ejaculator male rats: a central dopamine mediated effect? Neuropharmacology 2002; 42: 562–567.

    Article  Google Scholar 

  17. Heaton JP . Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neurosci Biobehav Rev 2000; 24: 561–569.

    Article  CAS  Google Scholar 

  18. Hull EM, Eaton RC, Markowski VP, Moses J, Lumley LA, Loucks JA . Opposite influence of medial preoptic D1 and D2 receptors on genital reflexes: implications for copulation. Life Sci 1992; 51: 1705–1713.

    Article  CAS  Google Scholar 

  19. Dula E, Keating W, Siami PF, Edmonds A, O'neil J, Buttler S . Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 2000; 56: 130–135.

    Article  CAS  Google Scholar 

  20. Martinez R, Puigvert A, Pomerol JM, Rodriguez-Villalba R . Clinical experience with apomorphine hydrochloride: the first 107 patients. J Urol 2003; 170 (6 Part 1): 2352–2355.

    Article  CAS  Google Scholar 

  21. Berde B . Pharmacology of ergot alkaloids in clinical use. Med J Aust 1978 4; 2 (3 Suppl): 3–13.

    CAS  PubMed  Google Scholar 

  22. Mantegani S, Brambilla E, Varasi M . Ergoline derivatives: receptor affinity and selectivity. Farmaco 1999 30; 54: 288–296.

    Article  CAS  Google Scholar 

  23. Rabey JM, Nissipeanu P, Inzelberg R, Korczyn AD . Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease. Clin Neuropharmacol 1994; 17: 286–293.

    Article  CAS  Google Scholar 

  24. Barbier P, Colelli A, Maggio R, Bravi D, Corsini GU . Pergolide binds tightly to dopamine D2 short receptors and induces receptor sequestration. J Neural Transm 1997; 104: 867–874.

    Article  CAS  Google Scholar 

  25. Pertz H, Eich E . O-Acylated lysergol and dihydrolysergol-I derivatives as competitive antagonists of 5-HT at 5-HT2 receptors of rat tail artery. Allosteric modulation instead of pseudoirreversible inhibition. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 394–401.

    Article  CAS  Google Scholar 

  26. Ikoma Y, Akai T, Nakata Y, Hara K, Wachtel H, Yamaguchi M . Effects of terguride, an ergot alkaloid derivative, on the central nervous system: biochemical and behavioral studies. Nippon Yakurigaku Zasshi 1993; 102: 113–129.

    Article  CAS  Google Scholar 

  27. Krisch I, Bole-Vunduk B . Behavioral studies on LEK-8804, a new ergoline derivative with potent 5-HT1A receptor agonist and 5-HT2 receptor antagonist activity. Pharmacol Biochem Behav 1994; 47: 301–305.

    Article  CAS  Google Scholar 

  28. Salvati P, Bondiolotti GP, Caccia C, Vaghi F, Bianchi G . Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in the spontaneously hypertensive rat. Pharmacology 1989; 38: 78–92.

    Article  CAS  Google Scholar 

  29. Krisch I, Budihna MV, Rucman R . Structure-activity study of some newly synthesized ergoline derivatives on 5-HT2 receptors and alpha-adrenoceptors in rabbit isolated aorta. Pharmacology 1992; 45: 195–208.

    Article  CAS  Google Scholar 

  30. Wiseman LR, Fitton A . Cabergoline; a review of its efficacy in the treatment of Parkinson's disease. CNS Drugs 1999; 12: 485–497.

    Article  CAS  Google Scholar 

  31. Olivier B, van Oorschot R, Waldinger MD . Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol 1998; 13 (Suppl 6): S9–S14.

    Article  Google Scholar 

  32. Waldinger MD, Zwinderman AH, Olivier B . Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol 2001; 21: 293–297.

    Article  CAS  Google Scholar 

  33. Kara H, Aydin S, Yucel M, Agargun MY, Odabas O, Yilmaz Y . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 1996; 156: 1631–1632.

    Article  CAS  Google Scholar 

  34. Lee HS, Song DH, Kim CH, Choi HK . An open clinical trial of fluoxetine in the treatment of premature ejaculation. J Clin Psychopharmacol 1996; 16: 379–382.

    Article  CAS  Google Scholar 

  35. Jahnichen S, Horowski R, Pertz HH . Agonism at 5-HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 2005 25; 513: 225–228.

    Article  Google Scholar 

  36. Rains CP, Bryson HM, Fitton A . Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995; 49: 255–279.

    Article  CAS  Google Scholar 

  37. Foreman MM, Wernicke JF . Approaches for the development of oral drug therapies for erectile dysfunction. Semin Urol 1990; 8: 107–112.

    CAS  PubMed  Google Scholar 

  38. Inzelberg R, Nisipeanu P, Rabey MJ, Korczyn AD . Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Mov Disord 1995; 10: 604–607.

    Article  CAS  Google Scholar 

  39. Steiger MJ, El-Debas T, Anderson T, Findley LJ, Marsden CD . Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996; 243: 68–72.

    Article  CAS  Google Scholar 

  40. Ahlskog JE, Wright KF, Muenter MD, Adler CH . Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996; 19: 202–212.

    Article  CAS  Google Scholar 

  41. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996; 46: 1062–1065.

    Article  CAS  Google Scholar 

  42. Calon F, Morissette M, Goulet M, Grondin R, Blanchet PJ, Bedard PJ et al. 125I-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments. Exp Neurol 2000; 163: 191–199.

    Article  CAS  Google Scholar 

  43. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993 7; 270: 83–90.

  44. McMahon CG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998; 159: 1935–1938.

    Article  CAS  Google Scholar 

  45. Manasia P, Pomerol J, Ribe N, Gutierrez del Pozo R, Alcover Garcia J . Comparison of the efficacy and safety of 90 mg versus 20 mg fluoxetine in the treatment of premature ejaculation.J Urol 2003; 170: 164–165.

    Article  CAS  Google Scholar 

  46. Christiansen E, Guirguis WR, Cox D, Osterloh IH, Sildenafil Multicentre Study Group. Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int J Impot Res 2000; 12: 177–182.

    Article  CAS  Google Scholar 

  47. Padma-Nathan H, Steers WD, Wicker PA . Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: a double-blind, placebo-controlled study of 329 patients. Sildenafil Study Group. Int J Clin Pract 1998; 52: 375–379.

    CAS  Google Scholar 

  48. Steers WD, the Sildenafil Study Group. Sildenafil (Viagra™) is effective in the treatment of severe male erectile dysfunction. Int J Impot Res 1998; 10: S4.

    Google Scholar 

  49. El-Galley R, Rutland H, Talic R, Keane T, Clark H . Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2001; 166: 927–931.

    Article  CAS  Google Scholar 

  50. Guay AT . Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 2002; 168: 205–206.

    Article  Google Scholar 

  51. Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005; 47: 518–522.

    Article  Google Scholar 

  52. Atiemo HO, Szostak MJ, Sklar GN . Salvage of sildenafil failures referred from primary care physicians. J Urol 2003; 170 (6 Part 1): 2356–2358.

    Article  Google Scholar 

  53. Jarow JP, Nana-Sinkam P, Sabbagh M, Eskew A . Outcome analysis of goal directed therapy for impotence. J Urol 1996; 155: 1609–1612.

    Article  CAS  Google Scholar 

  54. Knispel HH, Huland H . Influence of cause on choice of therapy in 174 patients with erectile dysfunction. J Urol 1992; 147: 1274–1276.

    Article  CAS  Google Scholar 

  55. Porst H . Editorial comment. J Urol 1999; 162: 1992.

    Article  Google Scholar 

  56. Hull EM, Lorrain DS, Du J, Matuszewich L, Lumley LA, Putnam SK et al. Hormone-neurotransmitter interactions in the control of sexual behavior. Behav Brain Res 1999 1; 105: 105–116.

    Article  CAS  Google Scholar 

  57. Mas M . Neurobiological correlates of masculine sexual behavior. Neurosci Biobehav Rev 1995; 19: 261–277.

    Article  CAS  Google Scholar 

  58. Bradley KC, Meisel R . Sexual behavior induction of c-Fos in the nucleus accumbens and amphetamine-stimulated locomotor activity are sensitized by previous sexual experience in female Syrian hamsters. J Neurosci 2001 15; 21: 2123–2130.

    Article  CAS  Google Scholar 

  59. Fiorino DF, Coury A, Phillips AG . Dynamic changes in nucleus accumbens dopamine efflux during the Coolidge effect in male rats. J Neurosci 1997 15; 17: 4849–4855.

    Article  CAS  Google Scholar 

  60. Robbins TW, Everitt BJ . Functions of dopamine in the dorsal and ventral striatum. Semin Neurosci 1992; 4: 119–128.

    Article  Google Scholar 

  61. Paoletti AM, Cagnacci A, Depau GF, Orru M, Ajossa S, Melis GB . The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 1996; 66: 527–532.

    Article  CAS  Google Scholar 

  62. Kruger TH, Haake P, Haverkamp J, Kramer M, Exton MS, Saller B et al. Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol 2003; 179: 357–365.

    Article  CAS  Google Scholar 

  63. Okkens AC, Bevers MM, Dieleman SJ, Willems AH . Shortening of the interoestrous interval and the lifespan of the corpus luteum of the cyclic dog by bromocryptine treatment. Vet Q 1985; 7: 173–176.

    Article  CAS  Google Scholar 

  64. Kooistra HS, Okkens AC, Bevers MM, Popp-Snijders C, van Haaften B, Dieleman SJ et al. Bromocriptine-induced premature oestrus is associated with changes in the pulsatile secretion pattern of follicle-stimulating hormone in beagle bitches. J Reprod Fertil 1999; 117: 387–393.

    Article  CAS  Google Scholar 

  65. Jochle W, Arbeiter K, Post K, Ballabio R, D'Ver AS . Effects on pseudopregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats. J Reprod Fertil Suppl 1989; 39: 199–207.

    CAS  PubMed  Google Scholar 

  66. Lera G, Vaamonde J, Rodriguez M, Obeso JA . Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993; 43: 2587–2590.

    Article  CAS  Google Scholar 

  67. Safarinejad MR . Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. J Diabet Complications 2004; 18: 205–210.

    Article  Google Scholar 

  68. Rendell MS, Rajfer J, Wicker PA, Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA 1999 3; 281: 421–426.

    Article  CAS  Google Scholar 

  69. Virag R . Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 1999; 54: 1073–1077.

    Article  CAS  Google Scholar 

  70. McMahon CG, Samali R, Johnson H . Treatment of intracorporeal injection nonresponse with sildenafil alone or in combination with triple agent intracorporeal injection therapy. J Urol 1999; 162: 1992–1997.

    Article  CAS  Google Scholar 

  71. Atmaca M, Tezcan E, Kuloglu M, Ustundag B . Serum leptin levels in obsessive-compulsive disorder. Psychiatr Clin Neurosci 2005; 59: 189–193.

    Article  CAS  Google Scholar 

  72. Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B . Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998; 18: 274–281.

    Article  CAS  Google Scholar 

  73. Berendsen HH, Broekkamp CL . Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol 1990; 101: 667–673.

    Article  CAS  Google Scholar 

  74. Safarinejad MR, Hosseini SY . Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Int J Impot Res 2005; 18: 164–169.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology and Nephrology Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran

    M R Safarinejad

Authors
  1. M R Safarinejad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M R Safarinejad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Safarinejad, M. Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. Int J Impot Res 18, 550–558 (2006). https://doi.org/10.1038/sj.ijir.3901476

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901476

Keywords

This article is cited by

Search

Advanced search

Quick links